Corporate | 29 July 2015 07:30

Press Release: 4SC AG announces formal closing of capital increase

4SC AG / Key word(s): Capital Increase/Miscellaneous

2015-07-29 / 07:30

Press Release

NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN.

4SC AG announces formal closing of capital increase

– Share capital increased from EUR 10,216,646.00 to EUR 18,966,646.00, gross issue proceeds of EUR 29 million at the top end of the targeted volume range.

– Cash capital increase and capital increase against contributions in kind entered in the commercial register.

– Upon completion of 4SC’s Annual General Meeting on 27 July 2015 and admission of the new shares from the capital increase against contributions in kind for trading on 28 July 2015, all 4SC shares are trading under the same ISIN (DE000A14KL72), German SIN (WKN A14KL7) and stock exchange symbol (VSC) starting today.

Planegg-Martinsried, Germany, 29 July 2015 – 4SC AG (Frankfurt, Prime Standard: ISIN DE000A14KL72, VSC) announced today that the capital increase for the funding of its research and development programmes in the field of cancer therapies, in particular a planned clinical Phase II trial with its lead oncology compound resminostat in the indication of cutaneous T-cell lymphoma (CTCL), resolved on 22 June 2015 has been formally closed.

As announced in the ad hoc release on 7 July 2015, in a cash capital increase and a capital increase against contributions in kind the share capital of 4SC AG has been increased from EUR 10,216,646.00, composed of 10,216,646 no-par value bearer shares, by EUR 8,750,000.00 or 8,750,000 shares to a total of EUR 18,966,646.00, composed of 18,966,646 shares, while partially utilising authorised capital. In the cash capital increase, 7,250,000 offered shares were placed at a subscription price of EUR 4.00 with existing shareholders in a rights issue and with selected new institutional investors in a subsequent rump placement. This resulted in gross issue proceeds of EUR 29 million, representing the upper end of the targeted volume range. Furthermore, a total of 1,500,000 consideration shares were issued at the issue price of EUR 4.00 by way of a capital increase against contributions in kind in order to swap a substantial portion of EUR 6 million of a shareholder loan into equity. The cash capital increase was entered in the commercial register on 9 July 2015, the capital increase against contributions in kind was entered in the commercial register on 17 July 2015.

From the start of share trading today (29 July 2015), all old and new 4SC shares are trading under the same ISIN (DE000A14KL72), German securities identification number (WKN) (A14KL7) and stock exchange symbol (VSC). As stated in the ad hoc release on 7 July 2015, the new shares from the cash capital increase were temporarily traded with the ISIN DE000A14KD72, the WKN A14KD7 and the stock exchange symbol VSCJ from 10 July 2015 until 27 July 2015, the day of 4SC’s Annual General Meeting. The new shares from the capital increase against contributions in kind received admission for trading yesterday (28 July 2015) and are included in stockmarket trading starting today (29 July 2015).

Baader Bank AG acted as Global Coordinator and Sole Bookrunner for the rights offering.

Release ends

About 4SC
4SC discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various cancer and autoimmune indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company’s pipeline comprises promising products that are in various stages of clinical development. 4SC’s aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies. Founded in 1997, 4SC had a headcount of 68 employees (60 FTEs) at 30 June 2015. 4SC AG (ISIN DE000A14KL72) has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

Legal note
These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities in the United States, Germany or any other jurisdiction. The shares (the “Shares”) of 4SC AG (the “Company”) may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. The Company does not intend to register any portion of the offering in the United States or to conduct a public offering of Shares in the Company in the United States.

This publication constitutes neither an offer to sell nor a solicitation to buy securities. The offer was made solely by means of, and on the basis of, a securities prospectus. The prospectus is available for free at 4SC AG, Am Klopferspitz 19a, 82152 Planegg-Martinsried, Germany, and on the websites of 4SC AG at www.4SC.de and www.capital.4SC.de.

The securities have already been sold.

Cautionary statement regarding forward-looking statements
This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and 4SC AG has no obligation to update any such information or to correct any inaccuracies herein or omission herefrom which may become apparent.

For more information please visit www.4sc.com or contact:

4SC AG
Jochen Orlowski, Corporate Communications & Investor Relations
jochen.orlowski(at)4sc.com, Tel.: +49-89-7007-6366

MC Services
Katja Arnold
katja.arnold(at)mc-services.eu, Tel.: +49-89-2102-2840

2015-07-29 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

Language:	English
Company:	4SC AG
	Am Klopferspitz 19a
	82152 Martinsried
	Germany
Phone:	+49 (0)89 7007 63-0
Fax:	+49 (0)89 7007 63-29
E-mail:	public@4sc.com
Internet:	www.4sc.de
ISIN:	DE000A14KL72
WKN:	A14KL7
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange

End of News DGAP News-Service

381691  2015-07-29